Latest Regulatory News

Jupiter Energy remained operationally cashflow positive in FY2026, but its cash position weakened sharply as revenue declined and drilling plans remained dependent on new funding. The Kazakhstan oil producer also carried US$13.87 million of interest-free promissory note debt after a post-year-end repayment.

H3 Energy has consolidated ownership of its Alinya hydrogen and helium project and reframed Warro as a potential commercial gas development, but its annual report warns that funding remains critical. The company ended FY2026 with A$900,434 in cash, net liabilities of A$551,671 and a material uncertainty over its ability to continue as a going concern.

Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.

KGL Resources says its Jervois copper project is funded through construction and ramp-up after a US$300 million Wheaton agreement and a post-year-end A$300 million equity raising. The company is now targeting a final investment decision in the second half of 2026 and first copper concentrate in 2028, while its annual report highlights the execution risks still attached to that timetable.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Emperor Energy has secured NOPSEMA approval for the Judith-2 appraisal well, removing a major regulatory barrier ahead of targeted drilling in April 2027. The well will test a 166 Bcf contingent gas resource and investigate deeper prospective sands, although commercial conversion remains unproven.

Silver Mines has built a substantially larger economic case for Bowdens, but the project still needs NSW approval before its 93.5 million ounce reserve can become a mine. The company is now funding the next phase with a A$70 million placement while absorbing dilution and a major royalty buy-back.

Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.

Amplitude Energy has approved development of its East Coast Supply Project, targeting first gas in 2028 and gross production of up to 90 TJ a day. The decision also adds an exploration well to the campaign, lifting FY27 capital expenditure guidance by up to $80 million.

Black Cat Syndicate’s gold inventory has fallen to 2.31Moz of Resources and 272koz of Reserves after mining depletion and model revisions. The producer is responding with up to $35 million of FY27 exploration spending while targeting 80-90koz of output.

Telix has secured FDA Fast Track designation for BiPASS, its Phase 3 program testing 68Ga-PSMA-PET alongside MRI before prostate biopsy. The milestone may support closer FDA engagement and faster review of a planned NDA, but the indication remains investigational and no BiPASS results were disclosed.

Enova Mining has launched a 1-for-4 entitlement offer at A$0.001 a share to raise up to A$495,152 for exploration and working capital. The modest raising sits alongside a proposed A$2 million placement and potential Caraubas acquisition issues that could materially expand the share count.